Clin2
NCT06431620Possibly a fitRecruiting

Thyroid cancer scan with help of a special hormone

Recombinant Human Thyroid Stimulating Hormone

Part of Cancer, Hormones & metabolism clinical trials.

This study tests if a man-made hormone (rhTSH) can make radioactive iodine therapy more effective for people with advanced thyroid cancer that has come back or spread. It aims to see if it helps find and treat cancer that doesn't respond well to standard radioactive iodine.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
15 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • Your thyroid cancer has come back or spread to other parts of the body.
  • You had your thyroid removed in a previous surgery.
  • You have at least one tumor that is 10 mm or bigger on a scan.
  • Your blood counts and kidney/liver function are within a certain range.
  • You have not had certain other cancer treatments or infections recently.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06405217Recruiting
Recombinant TSH for radioactive iodine therapy in thyroid cancer

This trial tests whether a medicine called recombinant human thyroid stimulating hormone (rhTSH) can help prepare your body for radioactive iodine (131I) treatment, which aims to destroy any remaining or spreading thyroid cancer cells. It may be a good option if your thyroid cancer has come back or spread and you are able to have radioactive iodine therapy.

Nanjing, Jiangsu
NCT03841617Recruiting· Phase 2
Measure radiation in thyroid cancer using a special PET-CT scan

This trial tests how much radiation a specialized whole-body PET/CT scan delivers in patients with differentiated thyroid cancer. It may help doctors better plan treatment for cancer that persists, returns, or has spread—especially when radioactive iodine (RAI) may or may not work.

Bethesda, Maryland
NCT04892303Recruiting· Phase 1
Planning treatment using radiation plus radioactive iodine for thyroid cancer

This Phase 1 study tests how doctors plan a combination of two radiation approaches—external beam radiation and radioactive iodine—for thyroid cancer that is not fully responding to standard treatment. It may help people who still have iodine-avid tumor spots, but whose iodine uptake looks too low to work well with radioactive iodine alone.

Baltimore, Maryland
NCT05024929Recruiting
Test targeted drugs to help radioactive iodine reach thyroid cancer

This study looks at whether certain cancer “targeted therapy” medicines can make radioactive iodine (RAI) therapy work better for thyroid cancer that has spread to the lungs. It also involves taking special whole-body scans to measure how much radioactive iodine gets taken up by the cancer.

San Francisco, California
NCT05575440Recruiting
Testing an iodine-like PET/CT scan for thyroid cancer

This study checks how well a new PET/CT scan (18F-TFB) can find thyroid cancer after a standard iodine whole-body scan. It may help doctors see where the cancer is using an added imaging test, which could improve planning for care.

Rochester, Minnesota
NCT06558981Recruiting· Phase 3
Radiation therapy after thyroid surgery for high-risk cancer

This trial is testing whether giving radiation therapy after thyroid surgery can help destroy any leftover cancer cells in people with high-risk differentiated thyroid cancer. It is for those who had surgery but some cancer was still left behind.

Shanghai

Hear when a new Recombinant Human Thyroid Stimulating Hormone trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.